B Cell Epitope Mapping of Zika

寨卡病毒 B 细胞表位作图

• 批准号: 9268498
• 负责人: DAVED FREMONT
• 金额: $ 39.99万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-30 至 2018-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9268498
• 关键词: Antibodies; Antibody-mediated protection; Award; B-Lymphocyte Epitopes; Bioterrorism; Computer software; Contracts; Data; Databases; Emerging Communicable Diseases; Epitope Mapping; Epitopes; Evaluation; Goals; Human; Humoral Immunities; Immune; In Vitro; Pathogenesis; Resources; Sampling; Toxin; Validation; Zika Virus; neutralizing antibody; novel; programs; therapeutic vaccine; vaccine development

The contracts awarded under this program support multi-disciplinary teams to identify novel B cell epitopes and elucidate mechanisms of antibody-mediated protection or pathogenesis that are important in humoral immunity in humans to emerging and re-emerging infectious diseases and potential agents of bioterrorism and their toxins. Each milestone-driven contract includes 1) epitope identification; 2) epitope validation that must include in vitro evaluation using human samples; 3) submission of epitope data, computer software, and structural data to the Immune Epitope Database and Analysis Resource; and 4) studies to help understand the mechanisms of protection or pathogenesis elicited by antibodies associated with the newly identified epitopes.

该计划授予的合同支持多学科团队识别新的 B 细胞表位，并阐明抗体介导的保护或发病机制，这些机制对于人类对新出现和重新出现的传染病和生物恐怖主义的潜在媒介及其体液免疫非常重要。毒素。每个里程碑驱动的合同包括 1) 表位识别； 2) 表位验证，必须包括使用人体样本进行体外评估； 3) 向免疫表位数据库和分析资源提交表位数据、计算机软件和结构数据； 4）帮助了解与新鉴定的表位相关的抗体引起的保护机制或发病机制的研究。